THREE FOCUS AREAS. ONE SHARED PURPOSE.
A world of data.
A reason to act.
Behind every number is a person. Explore the global picture of lung, kidney and bladder cancer—and the need for better care.
Explore the statistics GLOBOCAN 2024 · IARC / WHO estimatesUnderstanding today.
Changing tomorrow.
Loading the statistics explorer…
What do incidence and mortality mean?
Incidence is the estimated number of new diagnoses in 2024. Mortality is the estimated number of deaths from that cancer in 2024. These are population-level estimates, not individual predictions or a measure of survival.
Why colour the map by age-standardised rate?
An age-standardised rate (ASR) adjusts for differences in population age, using a world standard population. Rates are per 100,000 people. Case counts also reflect population size, so they should not be used alone to compare cancer risk.
What is five-year prevalence?
The estimated number of people alive who were diagnosed within the previous five years. It is a count of people, not a five-year survival percentage.
Which cancers and populations are included?
Lung: trachea, bronchus and lung (ICD-10 C33–34), both sexes. Kidney: kidney excluding renal pelvis (C64), both sexes. Bladder: bladder (C67), both sexes.
Where do the estimates come from?
International Agency for Research on Cancer (IARC), Global Cancer Observatory, GLOBOCAN 2024, version 1.0. Estimates depend on the availability and quality of cancer registration and mortality data in each country; precision varies. A zero is a published estimate, not missing data. Grey map areas have no matched estimate in this explorer.
Map boundaries are simplified for presentation and do not imply a position on territorial status. Some countries and territories are available through search and the table only.
